Bluebird bio Accounts Payable

Bluebird bio (BLUE) currently reports a accounts payable of $43M as of March 2025. That compares with $19M in the prior-year period — up 119.9% year over year. Use the charts on this page to explore Bluebird bio's accounts payable history and peer comparisons.

Bluebird bio's accounts payable increased from $19M to $43M — a 119.9% year-over-year increase (period ending March 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Bluebird bio reported $43M in accounts payable as of March 2025. That compares with $19M in the prior-year period — up 119.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $43M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Bluebird bio, and consider following BLUE for alerts when major investors trade the stock.

Bluebird bio is classified in the Healthcare sector. On accounts payable, it currently shows $43M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BLUE with unrelated industries.